|Address||Duran I Reynals Hospital – 3rd floor
Gran Via de l’hospitalet 199
08908 L’Hospitalet de Llobregat, Barcelona
|Platforms||ATMP & Biological, Biomarkers|
The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center established in 2004. Its stakeholders are Bellvitge University Hospital and Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology,University of Barcelona and the town council of L’Hospitalet de Llobregat.
IDIBELL is located in L’Hospitalet de Llobregat, south of Barcelona. It is a member of the Campus of International Excellence of the University of Barcelona HUBc and part of the CERCA institution of the Generalitat of Catalonia. In 2009, it became one of the first five Spanish research centers accredited as a health research institute by the Carlos III Institute of Health.
IDIBELL research is organized into 64 research groups strategically organized into three major scientific areas and 9 research programmes:
- Molecular Mechanisms and Experimental Therapy in Oncology Program
- Epigenetics and Cancer Biology Program
- Epidemiology, Public Health, Cancer Prevention and Palliative Care Program
- Neurosciences Program
- Diabetes and Metabolism Program
- Genes, Disease and Treatment Program
- Cardiovascular, Respiratory and Systemic Diseases and cellular aging Program
- Digestive system, diagnostics, pharmacogenetics, care support and clinical prevention program
- infectious disease and transplantation
IDIBELL has a strong track record in European projects and has a dedicated European Project Office. In addition, IDIBELL focuses much of its efforts on innovation and technology transfer in biomedicine, creating value for the continuous improvement of health and quality of life of patients.
IDIBELL has a total laboratory area of 5000m2, including shared areas a set of centralized core facilities dedicated to developing and providing research resources to assist campus biomedical researchers. In addition to the high-level basic research, IDIBELL also offers healthcare and clinical research within HUB, allowing a more effective transfer of scientific advances in the prevention and treatment of the most common health problems. Also integrated within the IDIBELL, the Catalan Institute of Oncology (ICO) is a comprehensive cancer centre devoted to minimize the cancer impact.
A key aspect of research in IDIBELL is its proximity to the patient. Because of its location and the healthcare activity that many of its researchers carry out, IDIBELL research groups can identify which problems are really priority and which solutions are effective in daily clinical practice.